Klebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution,
insertion, or deletion of amino acid sequence compared to wild bla KPC type, have reduced …

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

The Klebsiella pneumoniae carbapenemase (KPC), first described in the United States in
1996, is now a widespread global problem in several Gram-negative species. A worldwide …

Carbapenem resistance mediated by plasmid-borne Klebsiella pneumoniae
carbapenemases (KPC) is an emerging problem of significant clinical importance in Gram …

The emergence of Klebsiella pneumoniae carbapenemases (KPCs), β-lactamases that
inactivate “last-line” antibiotics such as imipenem, represents a major challenge to …

Avibactam is a novel β-lactamase inhibitor with affinity for Klebsiella pneumoniae
carbapenemases (KPCs). In combination with ceftazidime, the agent demonstrates activity …

Carbapenem-resistant Enterobacterales, such as Klebsiella pneumoniae carbapenemase
(KPC)-producing K. pneumoniae, represent a major threat to public health due to their rapid …

Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against
carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella pneumoniae …

The emergence of carbapenem-resistant Gram-negative pathogens poses a serious threat
to public health worldwide. In particular, the increasing prevalence of carbapenem-resistant …

The spread of β-lactamases that hydrolyze penicillins, cephalosporins and carbapenems
among Gram-negative bacteria has limited options for treating bacterial infections. Initially …